Visions Of The Arzerra Label To Come:More Oncology Indications In The Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Like Rituxan, another anti-CD20 MAb, Arzerra is also being developed for non-oncology markets, including immunology and neurology. Arzerra is also in active development for rheumatoid arthritis and multiple sclerosis patients.